Vanda Pharmaceuticals (STU:VM4) Cyclically Adjusted FCF per Share: €0.09 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:VM4 Vanda Pharmaceuticals Inc STU:VM4
72 GF Score
Price €5.12
GF Value €4.85
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Vanda Pharmaceuticals Cyclically Adjusted FCF per Share?

Vanda Pharmaceuticals STU:VM4 -2.48% 72 Cyclically Adjusted FCF per Share is €0.09 as of Mar. 2026. GuruFocus rates STU:VM4 with a GF Score™ of 72/100 and a GF Value™ of €4.85 (Fairly Valued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Vanda Pharmaceuticals's adjusted free cash flow per share for the three months ended in Mar. 2026 was €-0.879. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €0.09 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Vanda Pharmaceuticals's average Cyclically Adjusted FCF Growth Rate was -66.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Vanda Pharmaceuticals was 64.30% per year. The lowest was -126.80% per year. And the median was 8.25% per year.

As of today (2026-07-15), Vanda Pharmaceuticals's current stock price is €5.115. Vanda Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €0.09. Vanda Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is 56.83.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Vanda Pharmaceuticals was 1885.00. The lowest was 10.90. And the median was 32.05.


Vanda Pharmaceuticals  (STU:VM4) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Vanda Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=5.115/0.09
=56.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Vanda Pharmaceuticals was 1885.00. The lowest was 10.90. And the median was 32.05.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Vanda Pharmaceuticals Cyclically Adjusted FCF per Share Related Terms


Vanda Pharmaceuticals Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Vanda Pharmaceuticals's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vanda Pharmaceuticals Cyclically Adjusted FCF per Share Chart

Vanda Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.32 -0.10 0.07 0.38 0.13

Vanda Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.30 0.23 0.20 0.13 0.09

STU:VM4 vs AVIR, OABI, TENX: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Vanda Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vanda Pharmaceuticals Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vanda Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Vanda Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.


STU:VM4
72GF Score
Vanda Pharmaceuticals Inc STU:VM4
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vanda Pharmaceuticals Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Vanda Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.879/330.2130*330.2130
=-0.879

Current CPI (Mar. 2026) = 330.2130.

Vanda Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.067 241.018 -0.092
201609 0.025 241.428 0.034
201612 -0.025 241.432 -0.034
201703 -0.123 243.801 -0.167
201706 -0.057 244.955 -0.077
201709 0.034 246.819 0.045
201712 0.062 246.524 0.083
201803 0.025 249.554 0.033
201806 -0.328 251.989 -0.430
201809 0.134 252.439 0.175
201812 0.243 251.233 0.319
201903 0.155 254.202 0.201
201906 0.328 256.143 0.423
201909 0.095 256.759 0.122
201912 0.159 256.974 0.204
202003 -0.021 258.115 -0.027
202006 0.384 257.797 0.492
202009 0.140 260.280 0.178
202012 0.271 260.474 0.344
202103 0.135 264.877 0.168
202106 0.273 271.696 0.332
202109 0.140 274.310 0.169
202112 0.409 278.802 0.484
202203 0.064 287.504 0.074
202206 0.091 296.311 0.101
202209 0.225 296.808 0.250
202212 0.147 296.797 0.164
202303 0.517 301.836 0.566
202306 -0.213 305.109 -0.231
202309 -0.034 307.789 -0.036
202312 -0.063 306.746 -0.068
202403 0.120 312.332 0.127
202406 -0.112 314.175 -0.118
202409 -0.228 315.301 -0.239
202412 -0.033 315.605 -0.035
202503 -0.531 319.799 -0.548
202506 -0.229 322.561 -0.234
202509 -0.458 324.800 -0.466
202512 -0.427 324.054 -0.435
202603 -0.879 330.213 -0.879

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €0.09 mean?
Vanda Pharmaceuticals (STU:VM4) has a Cyclically Adjusted FCF per Share of €0.09 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Vanda Pharmaceuticals and its competitors.
Is Vanda Pharmaceuticals' Cyclically Adjusted FCF per Share too high?
Vanda Pharmaceuticals' current Cyclically Adjusted FCF per Share is €0.09. Overall, Vanda Pharmaceuticals has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vanda Pharmaceuticals' Cyclically Adjusted FCF per Share compare to AVIR and OABI?
Vanda Pharmaceuticals' Cyclically Adjusted FCF per Share of €0.09 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Vanda Pharmaceuticals and its competitors. Vanda Pharmaceuticals's current Cyclically Adjusted FCF per Share is €0.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vanda Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Vanda Pharmaceuticals (STU:VM4) is currently considered Fairly Valued. The stock's GF Value™ is €4.85, compared to a current price of €5.12 — trading 5.5% above its estimated fair value. The current Cyclically Adjusted FCF per Share is €0.09. Vanda Pharmaceuticals' overall GF Score™ is 72/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Vanda Pharmaceuticals (STU:VM4), the current Cyclically Adjusted FCF per Share is €0.09 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vanda Pharmaceuticals (STU:VM4) Overvalued in 2026?

Based on GuruFocus' analysis, Vanda Pharmaceuticals stock appears to be overvalued. The current stock price of €5.12 is trading 5.5% above its estimated GF Value™ of €4.85. GuruFocus considers Vanda Pharmaceuticals to be Fairly Valued.

Key valuation signals for STU:VM4:

  • Cyclically Adjusted FCF per Share: €0.09
  • GF Value™: €4.85 vs. price of €5.12 (5.5% above fair value)
  • GF Score™: 72/100 with 4 warning signs

No single metric tells the full story. See the STU:VM4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Vanda Pharmaceuticals Business Description

Other Exchanges VNDA:USA0LKB:UK
Address 2200 Pennsylvania Avenue North West, Suite 300 E, Washington, DC, USA, 20037
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
72GF Score

Get the complete analysis for STU:VM4

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.12
Price
€4.85
GF Value